<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318226</url>
  </required_header>
  <id_info>
    <org_study_id>ATX-1001</org_study_id>
    <secondary_id>R44NS059140</secondary_id>
    <nct_id>NCT01318226</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Multicenter, Parallel Group Study to Evaluate the Safety and Analgesic Activity of ATx08-001 When Administered to Subjects With Postherpetic Neuralgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aestus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Symbiance, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parallax Clinical Research, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aestus Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 randomized, double-blind, placebo-controlled, multiple-dose, multicenter,
      parallel-group study to evaluate the analgesic activity of ATx08-001, a novel selective
      peroxisome proliferator-activated receptor modulator (SPPARM), in subjects with
      moderate-to-severe postherpetic neuralgia pain. Eligible subjects will be randomized to
      receive either placebo or Atx08-001. Study drug will be administered orally twice a day for 7
      days. Subjects will be evaluated for neuropathic pain intensity at regular intervals over a 6
      hour period on Day 1 following the first dose of study drug. They will then be discharged
      from the clinic and will complete diary assessments of pain severity twice a day at home.
      Subjects will be asked to return to the clinic on Day 8 to complete their last set of pain
      evaluations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aestus has identified a novel selective peroxisome proliferator-activated receptor modulator
      (SPPARM), with promising potential for the treatment of neuropathic pain. PPARs are nuclear
      receptors that control many cellular and metabolic processes and are readily modulated by a
      variety of different drugs. Drugs modulating this target have been shown to improve blood
      glucose levels and levels of blood lipids, and may reduce the risk of atherosclerosis.

      The primary objective of the study is to evaluate the safety and analgesic efficacy of
      ATx08-001 at doses of 2.5 mg bid and 7.5 mg bid compared to placebo for the control of
      moderate-to-severe postherpetic neuralgia (PHN) pain.

      The secondary objectives are:

        -  To determine the approximate time to onset of analgesia following administration of
           study drug

        -  To determine the approximate duration of analgesia following study drug administration

        -  To determine the percentage of treatment responders among subjects receiving ATx08-001

      Subjects will be given a diary and instructed to record their postherpetic neuralgia pain
      severity on a Numerical Pain Rating Scale (NPRS - 12) &quot;over the past 12 hours&quot; on a 0 - 10
      scale with &quot;0&quot; being no pain and &quot;10&quot; being the most severe pain the subject could imagine,
      each morning and night for three consecutive days prior to returning for the Treatment Visit.

      The Treatment Visit will consist of an in-clinic 6-hour observation period. To be eligible
      for dosing, immediately before dosing subjects must report a baseline score of 4 or greater
      on the following Numerical Pain Rating Scale (NPRS-NOW) question: &quot;How would you rate your
      pain RIGHT NOW using a zero to ten scale, where zero equals no pain and ten is the worst pain
      you can imagine.&quot; Qualified subjects will be administered study drug followed by a 6-hour
      observation in-clinic period. In addition to the Baseline pain intensity assessment conducted
      just prior to drug administration (Time 0), pain intensity scores (pain right now) will be
      assessed using the NPRS-NOW at 30 minutes, 1, 2, 3, 4, and 6 hours following study drug
      administration. Pain relief compared with Baseline will be assessed at those same time points
      using a 5-point numerical pain relief (NPR) scale, where 0 = no relief, 1 = a little relief,
      2 = some relief, 3 = a lot of relief, and 4 = complete relief.

      Subjects will be discharged from the clinic at the end of the 6-hour observation period and
      will be instructed to record postherpetic neuralgia pain severity (NPRS-NOW scores) and pain
      relief (PAR scores) at 8, 10 and 12 hours following dosing in a diary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of the Pain Intensity Difference at 6 hours (SPID-6)</measure>
    <time_frame>Baseline to 6 hours after initial dose</time_frame>
    <description>Pain intensity will be measured with a numerical pain rating scale assessing &quot;pain right now&quot; where 0=no pain and 10=worst pain you can imagine. Pain intensity difference (PID) will be calculated by subtracting the pain intensity score at each time point from the Baseline pain intensity score. The SPID (Sum of the Pain Intensity Difference) score will be calculated by summing weighted PID scores over 6 hours, where the weight assigned to each PID score is equal to the elapsed time (in hours) since the previous scheduled evaluation time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-Hour Pain Intensity Scores Assessed with a Numerical Pain Rating Scale (NPRS-12)</measure>
    <time_frame>Seven Day Treatment Period</time_frame>
    <description>Pain intensity over the 7 day treatment period will be assessed using a numerical pain rating scale that assesses the subject's perception of average pain intensity over the past 12 hours (NPRS-12). The NPRS-12 will be completed by the subject every morning and evening for seven days. Pain intensity will be measured using an 11-point numerical scale where 0 = no pain and 10 = worst pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Summed Pain Intensity Difference (SPID) at Various Time Points</measure>
    <time_frame>1 hour period, 2 hour period, 4 hour period, 8 hour period, 10 hour period, 12 hour period</time_frame>
    <description>Pain intensity is measured with a numerical pain rating scale assessing &quot;pain right now&quot; where 0=no pain and 10=worst pain imaginable. Pain intensity difference (PID) is calculated by subtracting the pain intensity score at each time point from the Baseline pain intensity score. SPID (Sum of the Pain Intensity Difference) score will be calculated by summing weighted PID scores over the time period, where the weight assigned to each PID score is equal to the elapsed time since the previous scheduled time point. SPID will be assessed at 1,2,4,8,10 and 12 hours following first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief (TOTPAR) at 6 hours</measure>
    <time_frame>Baseline to 6 hours after initial dose</time_frame>
    <description>Pain relief will be assessed at 30 minutes, 1, 2, 3, 4, 6, 8, 10 and 12 hours following study drug administration using a numerical pain relief scale (NPR), where 0 = no relief, 1=little relief, 2=some relief, 3=a lot of relief, and 4 = complete relief. Total Pain Relief (TOTPAR) is calculated by summing the hourly NPR scores using the area under the NPR curve. TOTPAR will be assessed from Baseline to 6 hours following dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference (PID) at Various Time Points</measure>
    <time_frame>Baseline (prior to first dose), 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours after initial dose</time_frame>
    <description>Pain intensity scores (assessing pain right now) will be recorded using a numerical pain rating scale for pain right now (NPRS-NOW) at 30 minutes, 1, 2, 3, 4, 6, 8, 10 and 12 hours following study drug administration. Pain will be rated on an 11-point numerical scale where 0 = no pain and 10 = worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PAR) at Various Time Points</measure>
    <time_frame>Baseline (prior to first dose), 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours after initial dose</time_frame>
    <description>Pain relief compared with Baseline will be assessed at 30 minutes, 1, 2, 3, 4, 6, 8, 10 and 12 hours following study drug administration using a 5-point numerical pain relief (NPR) scale, where 0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, and 4 = complete relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject-rated Global Evaluation of Study Medication at 6 hours</measure>
    <time_frame>6 hours after initial dose (or immediately prior to receiving rescue medication)</time_frame>
    <description>At 6- hours following the first dose of study medication the subject will be asled to assess their overall impression of the study medication and rate it on a 5-point scale, where 0 = poor, 1 = fair, 2 = good, 3 = very good, 4 = excellent. Subjects will rate the study medication based on their perception of its efficacy and tolerability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject-rated Global Evaluation of Study Medication at the Follow-up Visit on Day 8</measure>
    <time_frame>Follow-up Visit</time_frame>
    <description>At the follow-up visit on Day 8, the subject will be asked to assess their overall impression of the study medication and rate it on a 5-point scale, where 0 = poor, 1 = fair, 2 = good, 3 = very good, 4 = excellent. Subjects will rate the study medication based on their perception of its efficacy and tolerability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief (TOTPAR) at 12 hours</measure>
    <time_frame>Baseline to 12 hours</time_frame>
    <description>Pain relief will be assessed at 30 minutes, 1, 2, 3, 4, 6, 8, 10 and 12 hours following study drug administration using a numerical pain relief scale (NPR), where 0 = no relief, 1=little relief, 2=some relief, 3=a lot of relief, and 4 = complete relief. Total Pain Relief (TOTPAR) is calculated by summing the hourly NPR scores using the area under the NPR curve. TOTPAR will be assessed until 12 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Rescue Medication Use</measure>
    <time_frame>Baseline to 6 hours after initial dose</time_frame>
    <description>Time to the first rescue medication use will be calculated by determining the number of minutes between the time the first dose of study drug was taken and the time of the first request for rescue analgesia. For subjects who did not take any rescue medication, the time to the first rescue medication use will be censored at the time of the final pain assessment during the observation period. If the time to event is greater than 6 hours, subjects will be assigned a time of 6 hours and will be considered censored in the statistical analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Responders at 6 Hours</measure>
    <time_frame>Baseline to 6 hours after initial dose</time_frame>
    <description>Subjects will be considered responders for the 6-hour observation period if they demonstrate at least 30% improvement in NPRS-NOW score, and a Pain Relief score &gt; 1, and a Global Evaluation Score of 2, 3, or 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain Scale (NPS) Ratings at Various Time Points</measure>
    <time_frame>Baseline (prior to initial dose), and at 1, 2, 4, and 6 hours and follow up visit</time_frame>
    <description>The Neuropathic Pain Scale (NPS) is an instrument designed to measure 6 different pain qualities (sharp, dull, hot, cold, sensitive, and itchy), the overall intensity of the pain, its subjective unpleasantness and two ratings of special characteristics (deep and surface pain) to characterize most manifestations of neuropathic pain on an 11-point categorical scale. The maximum total score is 100, with higher scores indicating greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tactile Allodynia Assessment at Various Time Points</measure>
    <time_frame>Baseline (prior to initial dose), and at 1, 2, 4, and 6 hours and follow up visit</time_frame>
    <description>Tactile Allodynia measures the patient's perception of innocuous stimuli as painful. A standard paintbrush (supplied by the Sponsor) will be brushed over a 5 cm area of skin at the site of maximum pain sensitivity and the subject will rate the severity of pain on a 100 mm VAS scale. The assessment will be performed on symmetrical dermatomes and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Responders for the Treatment Period</measure>
    <time_frame>Baseline to Day 8</time_frame>
    <description>Subjects will be considered responders for the 7-Day Treatment Period if they demonstrate a 30% improvement in NPRS-12 compared to the average NPRS-12 score from the three day period before the Treatment Visit, and if they report a Global Evaluation score of 2, 3, or 4.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Postherpetic Neuralgia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATx08-001 2.5 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg, twice a day approximately every 12 hours over an 8 day period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATx08-001 7.5 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 7.5 mg, twice a day approximately every 12 hours over an 8 day period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATx08-001</intervention_name>
    <description>ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg or 7.5 mg, twice a day approximately every 12 hours over an 8 day period.</description>
    <arm_group_label>ATx08-001 2.5 mg bid</arm_group_label>
    <arm_group_label>ATx08-001 7.5 mg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is able to provide written informed consent prior to study entry

          -  Is male or female, 18 - 85 years of age

          -  Has a diagnosis of postherpetic neuralgia that has been present for at least 3 months
             since the resolution of the skin rash (shingles), and has been associated with at
             least moderate pain

          -  Has a body mass index (BMI) between 17 and 36, inclusive

          -  Has on average postherpetic neuralgia pain severity of at least &quot;4&quot; on the 11-point
             NPRS-12 scale over three days prior to the Treatment Visit.

          -  At the Treatment Visit, entry into the study for dosing will require a baseline score
             of 4 or greater on the following 'Numerical Pain Rating Scale' (NPRS-NOW): &quot;How would
             you rate your pain RIGHT NOW using a zero to ten scale, where zero equals no pain and
             ten is the worst pain you can imagine.&quot; If the subject fails to qualify for the
             Treatment Visit because of a baseline pain score below 4, he or she may return on any
             day within a fourteen day period to attempt to qualify again. A subject will be
             allowed a maximum of two reassessments to qualify on the basis of the NPRS-NOW scale.

          -  Female subjects must be of non childbearing potential (defined as postmenopausal for
             at least 1 year or surgically sterile [bilateral tubal ligation, bilateral
             oophorectomy or hysterectomy]) or must be using adequate contraception (practicing one
             of the following methods of birth control):

          -  Total abstinence from sexual intercourse (minimum of one complete menstrual cycle
             before study entry),

          -  A partner who is physically unable to impregnate the subject (e.g., vasectomized)

          -  Contraceptives (oral, parenteral, or transdermal) for 3 consecutive months prior to
             study drug administration,

          -  Intrauterine device (IUD), or

          -  Double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal
             jellies or cream)

          -  If female of childbearing potential, subject must have a negative serum pregnancy test
             at screening

          -  Able to communicate meaningfully with the study observer and staff

          -  No known allergies to study medication

        Exclusion Criteria:

          -  Has another source of moderate-to-severe pain apart from the postherpetic neuralgia
             that might be confused with the PHN pain

          -  Is actively abusing alcohol or drugs

          -  Is unable to refrain from alcohol for a period beginning 24 hours prior to the
             treatment visit until the end of the study

          -  Is scheduled to undergo any surgical procedures during the period of study duration

          -  Has a history of any active serious medical conditions including cancer (with the
             exception of benign uterine dysplasia or removed skin carcinomas), cardiovascular,
             respiratory, renal, hepatic, gastrointestinal, endocrine, immunologic, hematologic,
             neurologic or psychiatric disease that would contraindicate study participation

          -  Has moderate to severe (New York Heart Association [NYHA] Class 3 or 4) heart failure
             defined as heart failure which significantly limits physical activity by provoking
             fatigue, palpitations or dyspnea.

          -  Has a history of either type 1 or type 2 diabetes mellitus

          -  Has taken a fixed scheduled opioid regimen within 3 days prior to the Treatment Visit.
             A fixed scheduled regimen of another type of analgesic, e.g., nonsteroidal
             antiinflammatory drug (NSAID) or an adjuvant analgesic will be allowed as long as the
             dose and schedule of administration were not changed for at least 2 weeks prior to
             dosing.

          -  Has used a short-acting &quot;as needed&quot; opioid less than 12 hours prior to dosing or an
             &quot;as needed&quot; NSAID dose less than 24 hours prior to dosing

          -  Has used extended duration oral analgesics up to 48 hours prior to the Treatment Visit

          -  Has applied lidocaine patches or dermal analgesics within 7 days prior to the
             Treatment Visit

          -  Has received an anesthetic block within two weeks of the Screening Visit

          -  Has received any prior neurolytic nerve block in the area of the PHN pain

          -  Is taking tricyclic, selective serotonin reuptake inhibitor (SSRI) or serotonin and
             noradrenaline reuptake inhibitor (SNRI) antidepressants for PHN (or for indications
             other than pain) and the dosage has been changed within 14 days of the Treatment
             Visit. Only subjects on stable doses from at least 14 days prior to the Treatment
             Visit through the duration of the study will be eligible to participate

          -  Is taking gabapentin (Neurontin), pregabalin (Lyrica), or duloxetine (Cymbalta) and
             the dosage has been changed within 14 days of the Treatment Visit. Only subjects
             receiving stable doses for at least 14 days prior to the Treatment Visit and are
             willing to continue taking the same doses for the duration of the study will be
             eligible to participate

          -  Has taken any medication that is a substrate of the cytochrome P450 enzyme CYP2C9
             within 4 days of dosing with study drug or is unwilling to refrain from such
             medications through the course of study drug treatment

          -  Has taken any prescription or over-the-counter medication within three days prior to
             the Treatment Visit, or herbal agents or other nutraceutical products within 14 days
             prior to the Treatment Visit, that in the opinion of the Investigator would be
             expected to confound the analgesic response

          -  Has documented liver failure or a serum ALT, AST, alkaline phosphatase, or GGT greater
             than 2.5 times the upper limit of normal, or total bilirubin greater than 1.5 times
             the upper limit of normal without a known, not clinically significant explanation

          -  Has a Brain Natriuretic Peptide (BNP) level &gt; 150 pg/mL

          -  Has a history of poorly controlled hyperthyroidism or hypothyroidism or Thyroid
             Stimulating Hormone (TSH) levels that are &lt; 0.3 or &gt; 5.5 ÂµlU/mL

          -  Has moderate or severe renal failure defined as a calculated creatinine clearance of &lt;
             60mL/min from the Cockcroft &amp; Gault formula

          -  Has a clinically significant abnormality on 12-lead electrocardiogram

          -  Has a known history of a positive Human Immunodeficiency Virus (HIV) antibody test or
             known HIV infection

          -  Has a history of a positive Hepatitis B core antibody, or anti-HCV antibody test

          -  Has previously been admitted to this study

          -  Has received an investigational medication within 30 days prior to the Treatment Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Research Center</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homestead Clinical Research</name>
      <address>
        <city>Cutler Bay (Miami)</city>
        <state>Florida</state>
        <zip>33189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <zip>48025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Clinical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2011</study_first_submitted>
  <study_first_submitted_qc>March 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <last_update_submitted>August 19, 2011</last_update_submitted>
  <last_update_submitted_qc>August 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postherpetic neuralgia</keyword>
  <keyword>shingles</keyword>
  <keyword>analgesia</keyword>
  <keyword>neuropathic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 12, 2015</submitted>
    <returned>May 4, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

